A phase II study of docetaxel and gemcitabine as a second line chemotherapy in cervical cancer.

Trial Profile

A phase II study of docetaxel and gemcitabine as a second line chemotherapy in cervical cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Docetaxel (Primary) ; Gemcitabine (Primary)
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Acronyms SCOTSERV
  • Most Recent Events

    • 30 Jan 2014 Accrual to date is 92% according to United Kingdom Clinical Research Network.
    • 07 Apr 2009 Company added as trial sponsor as reported by United Kingdom Clinical Research Network.
    • 07 Apr 2009 Planned end date changed from 31 Dec 2007 to 12 Feb 2009 as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top